It’s one of America’s best hospitals — a nonprofit “academic medical center” called the Cleveland Clinic. And this week it installed an IBM-managed quantum computer to accelerate healthcare research (according to an announcement from IBM). IBM is calling it “the first quantum computer in the world to be uniquely dedicated to healthcare research.”

The clinic’s CEO said the technology “holds tremendous promise in revolutionizing healthcare and expediting progress toward new cares, cures and solutions for patients.” IBM’s CEO added that “By combining the power of quantum computing, artificial intelligence and other next-generation technologies with Cleveland Clinic’s world-renowned leadership in healthcare and life sciences, we hope to ignite a new era of accelerated discovery.”

em>Inside HPC points out that “IBM Quantum System One” is part of a larger biomedical research program applying high-performance computing, AI, and quantum computing, with IBM and the Cleveland Clinic “collaborating closely on a robust portfolio of projects with these advanced technologies to generate and analyze massive amounts of data to enhance research.”
The Cleveland Clinic-IBM Discovery Accelerator has generated multiple projects that leverage the latest in quantum computing, AI and hybrid cloud to help expedite discoveries in biomedical research. These include:

– Development of quantum computing pipelines to screen and optimize drugs targeted to specific proteins;
– Improvement of a quantum-enhanced prediction model for cardiovascular risk following non-cardiac surgery;
– Application of artificial intelligence to search genome sequencing findings and large drug-target databases to find effective, existing drugs that could help patients with Alzheimer’s and other diseases.

The Discovery Accelerator also serves as the technology foundation for Cleveland Clinic’s Global Center for Pathogen & Human Health Research, part of the Cleveland Innovation District. The center, supported by a $500 million investment from the State of Ohio, Jobs Ohio and Cleveland Clinic, brings together a team focused on studying, preparing and protecting against emerging pathogens and virus-related diseases. Through the Discovery Accelerator, researchers are leveraging advanced computational technology to expedite critical research into treatments and vaccines.

Read more of this story at Slashdot.

IBM, along with 13 of its current and former executives, has been sued by investors who claim the IT giant used mainframe sales to fraudulently prop up newer, more trendy parts of its business. The Register reports: In effect, IBM deceived the market about its progress in developing Watson, cloud technologies, and other new sources of revenue, by deliberately misclassifying the money it was making from mainframe deals, assigning that money instead to other products, it is alleged. The accusations emerged in a lawsuit [PDF] filed late last week against IBM in New York on behalf of the June E Adams Irrevocable Trust. It alleged Big Blue shifted sales by its “near-monopoly” mainframe business to its newer and less popular cloud, analytics, mobile, social, and security products (CAMSS), which bosses promoted as growth opportunities and designated “Strategic Imperatives.”

IBM is said to have created the appearance of demand for these Strategic Imperative products by bundling them into three- to five-year mainframe Enterprise License Agreements (ELA) with large banking, healthcare, and insurance company customers. In other words, it is claimed, mainframe sales agreements had Strategic Imperative products tacked on to help boost the sales performance of those newer offerings and give investors the impression customers were clamoring for those technologies from IBM. “Defendants used steep discounting on the mainframe part of the ELA in return for the customer purchasing catalog software (i.e. Strategic Imperative Revenue), unneeded and unused by the customer,” the lawsuit stated.

IBM is also alleged to have shifted revenue from its non-strategic Global Business Services (GBS) segment to Watson, a Strategic Imperative in the CAMSS product set, to convince investors that the company was successfully expanding beyond its legacy business. Last April the plaintiff Trust filed a similar case, which was joined by at least five other law firms representing other IBM shareholders. A month prior, the IBM board had been presented with a demand letter from shareholders to investigate the above allegations. Asked whether any action has been taken as a result of that letter, IBM has yet to respond.

Read more of this story at Slashdot.

According to The Register, IBM has shifted the roles of US IBM Systems employees developing AIX over to the Indian office. From the report: Prior to this transition, said to taken place in the third quarter of 2022, AIX development was split more or less evenly between the US and India, an IBM source told The Register. With the arrival of 2023, the entire group had been moved to India. Roughly 80 US-based AIX developers were affected, our source estimates. We’re told they were “redeployed,” and given an indeterminate amount of time to find a new position internally, in keeping with practices we reported last week based on claims by other IBM employees.

Evidently, the majority of those redeployed found jobs elsewhere at IBM. A lesser number of staff are evidently stuck in “redeployment limbo,” with no IBM job identified and no evident prospects at the company. “It also appears that these people in ‘redeployment’ limbo within IBM are all older, retirement eligible employees,” our source said. “The general sense among my peers is that redeployment is being used to nudge older employees out of the company and to do so in a manner that avoids the type of scrutiny that comes with layoffs.”

Layoffs generally come with a severance payment and may have reporting requirements. Redeployments — directing workers to find another internal position, which may require relocating — can avoid cost and bureaucracy. They also have the potential to encourage workers to depart on their own. We’re told that IBM does not disclose redeployment numbers to its employees and does not report how internal jobs were obtained — through internal search, with the assistance of management — or were not obtained — employees left in limbo or who choose to leave rather than wait.

Read more of this story at Slashdot.

IBM has quietly announced it’s planning a 24-core Power 10 processor, seemingly to make one of its servers capable of running Oracle’s database in a cost-effective fashion. From a report: A hardware announcement dated December 13 revealed the chip in the following “statement of general direction” about Big Blue’s Power S1014 technology-based server: “IBM intends to announce a high-density 24-core processor for the IBM Power S1014 system (MTM 9105-41B) to address application environments utilizing an Oracle Database with the Standard Edition 2 (SE2) licensing model. It intends to combine a robust compute throughput with the superior reliability and availability features of the IBM Power platform while complying with Oracle Database SE2 licensing guidelines.”

Read more of this story at Slashdot.